Scott Gottlieb Quotes
The convergence of information technology and biology allows scientists to translate the human genome into digital data that can accelerate diagnoses and cures.
Gottlieb, Scott. "The Promise and Peril of 'Synthetic Biology'." The Wall Street Journal, 2016.
Science was progressing rapidly and Congress and the other legislatures of the world had not kept up with the scientific, legal or ethical implications of the progress. The result was that once a new technique was perfected, all the institutions were caught :flat footed, and sought out bioethicists to advise them.
Scott Gottlieb is an American physician and investor who served as the 23rd commissioner of the Food and Drug Administration (FDA) from 2017 until April 2019. He is presently a resident fellow at the conservative think tank the American Enterprise Institute (AEI), a partner at the venture capital firm New Enterprise Associates (NEA), a member of the board of directors of drug maker Pfizer, Inc, a member of the board of directors of Illumina, Inc., and a contributor to the cable financial news network CNBC. Before becoming FDA commissioner, he was a clinical assistant professor at New York University School of Medicine, the FDA deputy commissioner for medical and scientific affairs, a venture partner with New Enterprise Associates, a member of the policy board of the Leukemia & Lymphoma Society, a senior official at the Centers for Medicare and Medicaid Services, and a member of the Federal Health Information Technology Policy Committee, which advises the United States Department of Health and Human Services on healthcare information technology. He was previously a resident fellow at AEI from 2007 to 2017 prior to joining the FDA as commissioner in May 2017.